Pharmacodynamic Comparison of Two Formulations of Voglibose 0.3-mg Tablet |
Kim, Mi Jo
(Department of Clinical Pharmacology and Therapeutics, Asan Medical Center)
Lim, Hyeong-Seok (Department of Clinical Pharmacology and Therapeutics, Asan Medical Center) Cho, Sang-Heon (Department of Clinical Pharmacology, Inha University Hospital, Inha University School of Medicine) Bae, Kyun-Seop (Department of Clinical Pharmacology and Therapeutics, Asan Medical Center) |
1 | Oak W. Bioavailability and Bioequivalence Studies for Orally Administered DrugProducts - General Considerations. US Food and Drug Administration; 2003. |
2 | Vichayanrat A, Ploybutr S, Tunlakit M, Watanakejorn P. Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients. Diabetes Res Clin Pr, 2002;55(2):99-103. DOI |
3 | Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, Hanefeld M. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA(1c) level. Diabetes Care, 2000;23(12):1830-1834. DOI |
4 | Global Guideline for Type 2 Diabetes: International Diabetes Federation; 2012. |
5 | Draft Guidance on Acarbose. US Food and Drug Administration; 2009. |
6 | Cramp DG. New automated method for measuring glucose by glucose oxidase. J Clin Path, 1967;20:910-912. DOI |
7 | Zhang M, Yang J, Tao L, Li L, Ma P, Fawcett JP. Acarbose bioequivalence: exploration of new pharmacodynamic parameters. AAPS J, 2012; 14(2):345-351. DOI |
8 | Kageyama S, Nakamichi N, Sekino H, Nakano S. Comparison of the effects of acarbose and voglibose in healthy subjects. Clin Ther, 1997;19(4):720-729. DOI |